<!doctype html>
<html lang="en">
<head>
  <meta charset="utf-8" />
  <meta name="viewport" content="width=device-width, initial-scale=1" />
  <title>LiquidMammo™ | Breast cancer screening, reimagined</title>

  <!-- Canonical -->
  https://www.liquidmammo.com/

  <!-- SEO -->
  <meta name="description" content="LiquidMammo is a microRNA-based liquid biopsy for early breast cancer detection—non-invasive, clinician-ordered, and designed to complement imaging.">
  <meta name="keywords" content="breast cancer screening, microRNA test, liquid biopsy, early detection test, dense breasts screening, mammography complement, molecular breast cancer detection, microRNA breast cancer test, liquid biopsy breast cancer, LDT breast cancer test, non-invasive screening test, clinical decision support, molecular diagnostics, breast density screening, early-stage breast cancer detection">
  <meta name="theme-color" content="#E91E63" />

  <!-- Social -->
  <meta property="og:title" content="LiquidMammo™ | Breast cancer screening, reimagined">
  <meta property="og:description" content="A microRNA blood test designed to complement imaging; non-invasive, clinician-ordered, and density-aware.">
  <meta property="og:image" content="assets/logos/liquidmammo-logo.png">
  <meta property="og:type" content="website">
  <meta name="twitter:card" content="summary_large_image" />

  <!-- Favicon -->
  favicon.png

  <!-- Stylesheet -->
  <link rel="stylesheet" href="assets/css/styles.css" />
</head>

<body>

<!-- =========================
     HEADER / BRAND
========================== -->
<header>
  <div class="container">
    <nav>
      <div class="brand">
        <img src="assets/logos/liquidmammo-logo.png" alt="LiquidMammo logo">
        <strong>LiquidMammo™</strong>
      </div>

      <div class="nav-links">
        <a href="how-it-works.html">How It Works</a>
        <a href="science.html">Science</a>
        <a href="evidence.html">Evidence</a>
        <a href="patients.html">Patients</a>
        <a href="clinicians.html">Clinicians</a>
        <a href="biobank.html">Biobank</a>
        <a href="pricing.html">Pricing</a>
        <a href="contact.html">Contact</a>
        <a href="privacy.html">Privacy</a>
        <a href="#about">About</a>
      </div>
    </nav>
  </div>
</header>


<!-- =========================
     HERO
========================== -->
<section class="hero">
  <div class="container grid grid-2">

    <!-- TEXT -->
    <div>
      <span class="eyebrow">Non‑invasive • Clinician‑ordered • Density‑aware</span>

      <h1>Breast cancer screening, reimagined.</h1>

      <p class="kicker">A microRNA blood test designed to complement imaging.</p>

      <p class="small">
        Early molecular changes often precede structural findings on mammography. LiquidMammo provides a
        non‑invasive signal that strengthens clinical decision‑making—especially where breast density limits
        traditional imaging performance.
      </p>

      <div class="cta-row">
        <a class="btn" href="patients.html#join">Join Early Access</a>
        <a class="btn secondary" href="clinicians.html#enroll">Clinician Enrollment</a>
      </div>

      <p class="notice">
        Regulatory: LiquidMammo is being developed as a <strong>CLIA Laboratory Developed Test (LDT)</strong>;
        not yet FDA‑cleared/approved.
      </p>
    </div>

    <!-- IMAGE -->
    <div>
      <img src="https://images.unsplash.com/photo-1606205685561-2038323a6472?auto=format&fit=crop&w=1200&q=80"
           alt="Clinician handling blood tubes in a molecular diagnostics laboratory">
    </div>

  </div>
</section>


<!-- =========================
     WHY IT MATTERS
========================== -->
<section class="panel-light section">
  <div class="container grid grid-3">

    <div class="card-mini">
      <h4>Dense breasts challenge mammography</h4>
      <p class="small">
        Sensitivity drops to ~61% in extremely dense tissue. Interval cancers are more common. A molecular
        complement may reduce misses.
      </p>
    </div>

    <div class="card-mini">
      <h4>Earlier biological signal</h4>
      <p class="small">
        microRNA shifts can occur before imaging-visible lesions. Combining biology + imaging strengthens
        screening performance.
      </p>
    </div>

    <div class="card-mini">
      <h4>Addresses real‑world variability</h4>
      <p class="small">
        Mammographic detection varies by density, age, equipment, and reader. A standardized molecular layer
        improves consistency.
      </p>
    </div>

  </div>
</section>


<!-- =========================
     CLINICAL CONTEXT
========================== -->
<section class="section">
  <div class="container">

    <h2>Clinical context</h2>

    <div class="grid grid-3">

      <div class="stats-card">
        <ul class="list-tight">
          <li><strong>1 in 8</strong> cancers missed by mammography overall</li>
          <li><strong>Higher interval cancer rates</strong> in dense breasts</li>
          <li><strong>~50–60%</strong> false‑positive probability over 10 years</li>
        </ul>
      </div>

      <div class="stats-card">
        <ul class="list-tight">
          <li><strong>~61% sensitivity</strong> in extremely dense tissue</li>
          <li><strong>2–3 per 1,000</strong> cancers detected in younger women</li>
          <li><strong>Lower participation</strong> when imaging alone is used</li>
        </ul>
      </div>

      <div class="card note-card">
        <p class="small">
          LiquidMammo is designed to complement—not replace—imaging. By layering molecular signals with
          mammography, clinicians can contextualize risk, reduce uncertainty, and improve consistency across
          subgroups.
        </p>
      </div>

    </div>

  </div>
</section>


<!-- =========================
     HOW IT WORKS
========================== -->
<section class="panel-light section">
  <div class="container">

    <h2>How it works</h2>

    <div class="grid grid-3">

      <div class="card-mini">
        <h4>1 — Ordered by clinician</h4>
        <p class="small">Clinician‑initiated blood draw at routine visit; no preparation needed.</p>
      </div>

      <div class="card-mini">
        <h4>2 — microRNA profiling</h4>
        <p class="small">A proprietary multi‑marker panel quantifies tumor‑associated microRNA dysregulation.</p>
      </div>

      <div class="card-mini">
        <h4>3 — Actionable report</h4>
        <p class="small">Results delivered to clinicians with density‑aware interpretation and subgroup context.</p>
      </div>

    </div>

  </div>
</section>


<!-- =========================
     ABOUT MULTIOMICS (NEW)
========================== -->
<section id="about" class="section">
  <div class="container">

    <span class="eyebrow">About MultiOmics Inc.</span>
    <h2>Translating molecular signals into earlier, more equitable detection</h2>

    <div class="grid grid-3">

      <div class="card">
        <h3>Who we are</h3>
        <p class="small">
          MultiOmics Inc. develops LiquidMammo™, a microRNA‑based liquid biopsy designed to complement imaging in
          breast cancer screening. We are headquartered in Washington, DC, and operate out of LabCentral,
          Cambridge, MA (MIT innovation ecosystem).
        </p>
      </div>

      <div class="card">
        <h3>Scientific foundation</h3>
        <p class="small">
          Our approach leverages multi‑marker microRNA dysregulation associated with tumor biology. By combining
          molecular and imaging signals, LiquidMammo aims to strengthen clinical decision‑making—especially in
          populations where breast density reduces mammographic sensitivity.
        </p>
      </div>

      <div class="card">
        <h3>Team & advisors</h3>
        <p class="small">
          <!-- Replace later with verified details from your investor deck. -->
          Founding team with backgrounds in molecular diagnostics, oncology, and biostatistics; clinical advisors
          if approved for public use. -->
          We collaborate with leading academic clinicians to refine assay performance and evaluate clinical utility.
        </p>
      </div>

      <div class="card">
        <h3>Impact for patients</h3>
        <p class="small">
          A non‑invasive blood test can reduce anxiety from equivocal imaging, broaden access for individuals who
          defer imaging, and support earlier detection in dense breasts—without adding procedural burden.
        </p>
      </div>

      <div class="card">
        <h3>Business & access</h3>
        <p class="small">
          LiquidMammo is being advanced as a CLIA LDT with a focused early‑access rollout. The model emphasizes
          clinician adoption, payer engagement, and partnerships that support equitable screening access.
        </p>
      </div>

    </div>

  </div>
</section>


<!-- =========================
     FOOTER
========================== -->
<footer>
  <div class="container footer-grid">

    <div>
      <strong>LiquidMammo™</strong><br>
      A test developed by MultiOmics Inc.
      <p class="footer-note">
        MultiOmics Inc. is headquartered in Washington, DC, and operates out of LabCentral,
        Cambridge, MA (MIT innovation ecosystem).
      </p>
    </div>

    <div class="footer-logo">
      assets/logos/multiomics-logo.png
      <div class="footer-note" style="line-height:1.2">
        Developed by<br>MultiOmics Inc.
      </div>
    </div>

  </div>

  <div class="container footer-note" style="margin-top:20px;">
    © <script>document.write(new Date().getFullYear())</script> MultiOmics Inc. •
    privacy.htmlPrivacy & Compliance</a> •
    contact.htmlOrder / Kits</a>
  </div>
</footer>

</body>
</html>







